Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027

Avidity Biosciences (RNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $72.00 price target.

Kostas Biliouris has given his Buy rating due to a combination of factors related to Avidity Biosciences’ promising developments. The FDA’s endorsement of the Accelerated Approval pathway for Del-brax in treating FSHD is a significant milestone. This approval is based on the statistically significant reduction in the cDUX biomarker achieved by Del-brax, which suggests a high likelihood of meeting primary endpoints in upcoming studies.
Furthermore, the consistent efficacy and acceptable safety profile demonstrated in clinical trials for both Del-desiran and Del-brax highlight the potential for successful pivotal studies. These developments position Avidity Biosciences well for potential regulatory approvals by the first half of 2027, making the stock an attractive investment opportunity.

According to TipRanks, Biliouris is an analyst with an average return of -14.1% and a 33.75% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Legend Biotech, Sarepta Therapeutics, and Rocket Pharmaceuticals.

In another report released today, Citi also maintained a Buy rating on the stock with a $75.00 price target.